Safety of Whey basic protein isolates as a novel food pursuant to Regulation (EU) 2015/2283 - Université de Lille Accéder directement au contenu
Article Dans Une Revue EFSA Journal Année : 2018

Safety of Whey basic protein isolates as a novel food pursuant to Regulation (EU) 2015/2283

Jean-Louis Bresson
  • Fonction : Auteur
Barbara Burlingame
  • Fonction : Auteur
Tara Dean
  • Fonction : Auteur
Susan Fairweather-Tait
  • Fonction : Auteur
Marina Heinonen
  • Fonction : Auteur
Karen-Ildico Hirsch-Ernst
  • Fonction : Auteur
Inge Mangelsdorf
  • Fonction : Auteur
Harry J. Mcardle
  • Fonction : Auteur
Androniki Naska
  • Fonction : Auteur
Monika Neuhauser-Berthold
  • Fonction : Auteur
Grazyna Nowicka
  • Fonction : Auteur
Kristina Pentieva
  • Fonction : Auteur
Yolanda Sanz
  • Fonction : Auteur
Alfonso Siani
  • Fonction : Auteur
Anders Sjodin
  • Fonction : Auteur
Martin Stern
  • Fonction : Auteur
Daniel Tome
  • Fonction : Auteur
Marco Vinceti
  • Fonction : Auteur
Peter Willatts
  • Fonction : Auteur
Karl-Heinz Engel
  • Fonction : Auteur
Rosangela Marchelli
  • Fonction : Auteur
Annette Poting
  • Fonction : Auteur
Morten Poulsen
  • Fonction : Auteur
Josef Rudolf Schlatter
  • Fonction : Auteur
Mathias Amundsen
  • Fonction : Auteur
Henk van Loveren
  • Fonction : Auteur

Résumé

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on whey basic protein isolate as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is obtained by ion exchange chromatography of skimmed cow's milk. The applicant intends to market the NF in infant and follow-on formulae and meal replacement beverages, dietary foods for special medical purposes and as food supplements. The highest estimated intake of the NF based on the proposed uses and use levels would be 24.8 mg/kg body weight (bw) per day in infants and 27.8 in toddlers. The information provided on composition, specifications, production process and stability of the NF do not raise safety concerns. Taking into account the composition of the NF and the intended use levels, the Panel considers that the consumption of the NF is not nutritionally disadvantageous. The Panel considers that there is no concern with respect to genotoxicity. The no observed adverse effect level (NOAEL) of a subchronic 13-week rat study was 2000 mg/kg bw per day. Considering the source, the production process and nature of the NF, the Panel considers the margin of exposure (MOE) of 154 to be sufficient for the adult population (on a high-estimated intake of 13 mg/kg bw). For infants and toddlers, the MOE would be at least 81 and 72, respectively. Taking into account the composition of the NF, its source, the history of consumption of the main components of the NF, the production process and that the NOAEL in a subchronic rat study was the highest dose tested the Panel considers that also the MOE for infants and toddlers are sufficient. The Panel concludes that the novel food ingredient, whey basic protein isolate, is safe under the proposed uses and use levels.
Fichier principal
Vignette du fichier
EFSA Journal - 2018 - - Safety of Whey basic protein isolates as a novel food pursuant to Regulation EU 2015 2283.pdf (1.88 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04318659 , version 1 (01-12-2023)

Licence

Identifiants

Citer

Turck Turck, Jean-Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait, et al.. Safety of Whey basic protein isolates as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal, 2018, EFSA Journal, 16, ⟨10.2903/j.efsa.2018.5360⟩. ⟨hal-04318659⟩

Collections

RIIP UNIV-LILLE
16 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More